Clinical Trial Update: Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response [Phase 2]

View source ↗

Summary

Phase 2 trial update on inhaled TD-8236 for allergen-induced asthmatic response has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• TD-8236

Snippet

Sponsor: Theravance Biopharma | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2022-03-18